NowPatient vs Sesame
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
NowPatient
Best for early adopters who want Foundayo via a one-stop telehealth platformStarting at $199/mo
Sesame
Best for mainstream telehealth GLP-1 accessStarting at $199/mo
Side-by-Side Comparison
| Feature | NowPatient | Sesame |
|---|---|---|
| Overall Score | ✓7.1/10 | 6.9/10 |
| Starting Price | $199/mo | $199/mo |
| Customer Rating | — | — |
| Features | 3 features | 3 features |
| States Available | ✓51 | 50 |
| Compounded | — | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
NowPatient
Pros
- ✓Confirmed early Foundayo channel (April 2026 rollout)
- ✓Daily oral pill — no needles, no refrigeration
- ✓Telehealth consultation included
Cons
- ✗Pricing tier not yet publicly verified — confirm directly with the provider
- ✗State-by-state availability still being phased in
- ✗Lower mean weight loss vs injectable GLP-1s (~11.1% vs 14.9% Wegovy and 20.9% Zepbound at labeled max)
Sesame
Pros
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
Cons
- ✗Limited public information on program details
Our Verdict
NowPatient edges out Sesame with a higher overall score of 7.1/10 and is particularly strong for early adopters who want Foundayo via a one-stop telehealth platform. Sesame remains a solid alternative, especially if you're looking for mainstream telehealth GLP-1 access.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.